|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/4439 | |
| A61K 31/519 | |||
| A61K 31/5377 | |||
| A61K 45/06 | |||
| A61P 35/00 |
| (11) | Number of the document | 2726074 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12735408.2 |
| Date of filing the European patent application | 2012-07-02 | |
| (97) | Date of publication of the European application | 2014-05-07 |
| (45) | Date of publication and mention of the grant of the patent | 2018-04-04 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2012/045199 |
| Date | 2012-07-02 |
| (87) | Number | WO 2013/006532 |
| Date | 2013-01-10 |
| (30) | Number | Date | Country code |
| 201161503642 P | 2011-07-01 | US |
| (72) |
KIM, Sunkyu, US
DOSHI, Shivang, US
HAAS, Kristy, US
KOVATS, Steven, US
HUANG, Alan Xizhong, US
CHEN, Yan, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | COMBINATION THERAPY COMPRISING A CDK4/6 INHIBITOR AND A PI3K INHIBITOR FOR USE IN THE TREATMENT OF CANCER |
| COMBINATION THERAPY COMPRISING A CDK4/6 INHIBITOR AND A PI3K INHIBITOR FOR USE IN THE TREATMENT OF CANCER |